IDEAYA Biosciences (IDYA) Asset Utilization Ratio (2021 - 2026)

IDEAYA Biosciences (IDYA) reported Asset Utilization Ratio of 0.22 for Q1 2026, up 10.35% sequentially from 0.2 in Q4 2025.

IDEAYA Biosciences (IDYA) Asset Utilization Ratio (2021 - 2026) Analysis & Trends

IDEAYA Biosciences (IDYA) has 6 years of Asset Utilization Ratio data on file, last reported at 0.22 in Q1 2026.

For the quarter ending Q1 2026, Asset Utilization Ratio changed N/A year-over-year to 0.22; the trailing twelve-month figure through Mar 2026 stood at 0.22 (changed N/A YoY), and the FY2025 full-year result was 0.2, up 2380.9% from the prior year.
Asset Utilization Ratio grew to 0.22 in Q1 2026, from 0.2 in the prior quarter.
In the past five years, Asset Utilization Ratio ranged from a high of 0.22 in Q1 2026 to a low of 0.0 in Q3 2024.
A 5-year average of 0.09 and a median of 0.09 in 2022 frame the typical range for Asset Utilization Ratio.
Across the five-year window, Asset Utilization Ratio slumped 92.0% in 2024 and soared 5346.0% in 2025, its largest moves.
Tracing IDYA's Asset Utilization Ratio over 5 years: stood at 0.13 in 2022, then sank by 68.98% to 0.04 in 2023, then tumbled by 85.03% to 0.01 in 2024, then jumped by 3222.1% to 0.2 in 2025, then climbed by 10.35% to 0.22 in 2026.
Business Quant data shows IDYA's Asset Utilization Ratio at 0.22 in Q1 2026, 0.2 in Q4 2025, and 0.19 in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Asset Util. (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	0.69
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	0.47
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	0.37
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	IDEAYA Biosciences	3.21 Bn	2.54 Bn	-	0.22

Download Data